About MEI Pharma (NASDAQ:MEIP)
MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacturing, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio30.71
Forward P/E Ratio-2.26
Sales & Book Value
Annual Sales$23.25 million
Price / Sales3.43
Cash Flow$0.0755 per share
Price / Cash28.48
Book Value$1.38 per share
Price / Book1.56
EPS (Most Recent Fiscal Year)$0.07
Net Income$2.67 million
Return on Equity-42.23%
Return on Assets-38.25%
MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma (NASDAQ:MEIP) released its earnings results on Thursday, February, 8th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.10. The company had revenue of $0.36 million for the quarter, compared to analysts' expectations of $1 million. MEI Pharma had a negative net margin of 354.10% and a negative return on equity of 42.23%. View MEI Pharma's Earnings History.
What price target have analysts set for MEIP?
3 equities research analysts have issued 1-year price targets for MEI Pharma's shares. Their predictions range from $6.50 to $7.00. On average, they expect MEI Pharma's share price to reach $6.8333 in the next year. View Analyst Ratings for MEI Pharma.
What are Wall Street analysts saying about MEI Pharma stock?
Here are some recent quotes from research analysts about MEI Pharma stock:
- 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (4/12/2018)
- 2. Cann analysts commented, "MEI Pharma’s F2Q loss per share of $0.16 was higher than our estimated $0.09, due to operating expenses of $6.5 million, or 50.2% higher than our estimated $4.3 million. The higher than estimated expenses stemmed primarily from higher R&D expenses and costs associated with collaboration revenues. Higher R&D expenses are attributed to voruciclib expenses and increased R&D for ME-401. Our outlook for FY2019-23 revenue remains basically unchanged. Our FY2018 loss per share foreacast is being increased by 12% to account for higher anticipated R&D expense and costs associated with collaboration revenue." (2/8/2018)
Who are some of MEI Pharma's key competitors?
Some companies that are related to MEI Pharma include Tetraphase Pharmaceuticals (TTPH), Acer Therapeutics (ACER), Sierra Oncology (SRRA), Aeglea Bio Therapeutics (AGLE), Aldeyra Therapeutics (ALDX), BioXcel Therapeutics (BTAI), Affimed (AFMD), Zynerba Pharmaceuticals (ZYNE), BioDelivery Sciences International (BDSI), Checkpoint Therapeutics (CKPT), Adamis Pharmaceuticals (ADMP), Galectin Therapeutics (GALT), Axovant Sciences (AXON), AcelRx Pharmaceuticals (ACRX), Otonomy (OTIC), Bellerophon Therapeutics (BLPH), ContraFect (CFRX) and Trevena (TRVN).
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the folowing people:
- Dr. Daniel P. Gold Ph.D., Pres, CEO & Director (Age 64)
- Mr. Brian G. Drazba CPA, Sec. & CFO (Age 57)
- Mr. David M. Urso Esq., J.D., Sr. VP of Corp. Devel. and Gen. Counsel (Age 54)
- Dr. Robert D. Mass M.D., Chief Medical Officer (Age 64)
- Dr. Karen E. Potts Ph.D., Sr. VP of Regulatory Affairs (Age 55)
Has MEI Pharma been receiving favorable news coverage?
Media headlines about MEIP stock have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MEI Pharma earned a news impact score of 0.16 on Accern's scale. They also gave press coverage about the company an impact score of 47.44 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of MEI Pharma?
Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MEI Pharma's stock price today?
One share of MEIP stock can currently be purchased for approximately $2.15.
How big of a company is MEI Pharma?
MEI Pharma has a market capitalization of $78.92 million and generates $23.25 million in revenue each year. The company earns $2.67 million in net income (profit) each year or $0.07 on an earnings per share basis. MEI Pharma employs 25 workers across the globe.
How can I contact MEI Pharma?
MEI Pharma's mailing address is 3611 VALLEY CENTRE DRIVE SUITE 500, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]
MarketBeat Community Rating for MEI Pharma (MEIP)MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
MEI Pharma (NASDAQ:MEIP) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
MEI Pharma (NASDAQ MEIP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.25%
Institutional Ownership Percentage: 23.51%
MEI Pharma (NASDAQ MEIP) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/27/2017||Charles V Baltic III||Director||Buy||11,000||$2.25||$24,750.00||13,250|| |
|11/9/2015||Vivo Ventures Vii, Llc||Major Shareholder||Sell||390,572||$1.84||$718,652.48|| |
|1/21/2015||Charles V Baltic III||Director||Buy||5,000||$3.81||$19,050.00|| |
|12/9/2014||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||79,085||$6.01||$475,300.85|| |
|12/8/2014||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||9,004||$6.05||$54,474.20|| |
|6/30/2014||Charles V Baltic III||Director||Buy||2,000||$6.56||$13,120.00|| |
|10/29/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||299,609||$8.21||$2,459,789.89|| |
|10/2/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||581,646||$10.16||$5,909,523.36|| |
|8/16/2013||Charles V Baltic III||Director||Buy||2,600||$6.82||$17,732.00|| |
|6/28/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||7,337||$7.58||$55,614.46|| |
|6/11/2013||Vivo Ventures V, Llc||Major Shareholder||Sell||13,727||$7.80||$107,070.60|| |
|5/16/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||17,428||$9.07||$158,071.96|| |
|5/8/2013||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||200,000||$8.58||$1,716,000.00|| |
|1/25/2013||Charles V Baltic III||Director||Buy||10,200||$6.04||$61,608.00|| |
|12/21/2012||Charles V Baltic III||Director||Buy||3,500||$7.18||$25,130.00|| |
MEI Pharma (NASDAQ MEIP) News Headlines
|MEI Pharma (MEIP) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - April 17 at 4:17 PM
|MEI Pharma (MEIP) Now Covered by Laidlaw|
www.americanbankingnews.com - April 12 at 11:47 AM
|MEI Pharma (MEIP) Downgraded by Zacks Investment Research to "Hold"|
www.americanbankingnews.com - April 12 at 10:07 AM
|MEI Pharma (MEIP) Upgraded to Buy by Zacks Investment Research|
www.americanbankingnews.com - April 11 at 8:58 AM
|MEI Pharma (MEIP) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - April 1 at 1:34 PM
|MEI Pharma (MEIP) PT Set at $7.00 by Oppenheimer|
www.americanbankingnews.com - March 30 at 12:05 PM
|MEI Pharma (MEIP) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - March 29 at 6:22 PM
|MEI Pharma (MEIP) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow|
seekingalpha.com - March 28 at 5:20 PM
|MEI Pharma (MEIP) Lifted to "Hold" at ValuEngine|
www.americanbankingnews.com - March 25 at 11:21 AM
|Cann Reiterates Buy Rating for MEI Pharma (MEIP)|
www.americanbankingnews.com - March 21 at 4:40 PM
|MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors|
finance.yahoo.com - February 26 at 8:48 AM
|MEI Pharma's early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1% - Seeking Alpha|
seekingalpha.com - February 14 at 7:27 AM
|MEI Pharma (MEIP) Says Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients ... - StreetInsider.com|
www.streetinsider.com - February 14 at 7:27 AM
|MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer|
finance.yahoo.com - February 13 at 3:28 PM
|MEI Pharma (MEIP) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - February 10 at 7:24 AM
|MEI Pharma Reports Second Quarter Fiscal Year 2018 Results - PR Newswire (press release)|
www.prnewswire.com - February 9 at 7:16 AM
|MEI Pharma Reports Second Quarter Fiscal Year 2018 Results|
finance.yahoo.com - February 8 at 3:28 PM
|Cann Reaffirms Buy Rating for MEI Pharma (MEIP)|
www.americanbankingnews.com - February 8 at 2:38 PM
|Head-To-Head Contrast: Gemphire Therapeutics (GEMP) versus MEI Pharma (MEIP)|
www.americanbankingnews.com - January 28 at 9:14 PM
|MEI Pharma (MEIP) versus Its Competitors Head to Head Analysis|
www.americanbankingnews.com - January 14 at 11:30 AM
|ETF Preview: ETFs, Futures Strain to Recover from Weakness Sparked by Bond-Market Woes; Street Mulls Jobless Claims, PPI Data|
www.nasdaq.com - January 11 at 9:33 AM
|MEI Pharma (MEIP) Granted FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib|
www.streetinsider.com - January 8 at 5:42 PM
|Critical Comparison: MEI Pharma (MEIP) & Its Rivals|
www.americanbankingnews.com - January 3 at 11:30 PM
|Head to Head Comparison: MEI Pharma (MEIP) & The Competition|
www.americanbankingnews.com - January 1 at 7:28 AM
|MEI Pharma (MEIP) vs. The Competition Critical Contrast|
www.americanbankingnews.com - December 29 at 7:24 PM
|MEI Pharma (MEIP) versus The Competition Head-To-Head Analysis|
www.americanbankingnews.com - December 29 at 5:28 AM
|ETFs with exposure to MEI Pharma, Inc. : December 25, 2017|
finance.yahoo.com - December 25 at 3:30 PM
|MEI Pharma (MEIP) Says Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports - StreetInsider.com|
www.streetinsider.com - December 23 at 6:05 AM
|MEI Pharma's (MEIP) Buy Rating Reaffirmed at Cann|
www.americanbankingnews.com - December 21 at 4:28 PM
|MEI Pharma (MEIP) Given a $7.00 Price Target at Oppenheimer|
www.americanbankingnews.com - December 21 at 4:28 PM
|MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports|
finance.yahoo.com - December 21 at 9:14 AM
|ETFs with exposure to MEI Pharma, Inc. : December 12, 2017|
finance.yahoo.com - December 12 at 6:01 PM
|MEI Pharma's (MEIP) Buy Rating Reiterated at Oppenheimer|
www.americanbankingnews.com - December 11 at 5:08 PM
|MEI Pharma (MEIP) Receives "Buy" Rating from Cann|
www.americanbankingnews.com - December 11 at 9:00 AM
|MEI Pharma (MEIP) Rating Lowered to Sell at ValuEngine|
www.americanbankingnews.com - December 3 at 8:14 AM
|MEI Pharma Inc (MEIP) Director Charles V. Baltic III Acquires 11,000 Shares|
www.americanbankingnews.com - November 29 at 8:46 PM
|Short Interest in MEI Pharma Inc (MEIP) Drops By 82.9%|
www.americanbankingnews.com - November 29 at 2:38 AM
|MEI Pharma to Host Annual Meeting of Stockholders|
finance.yahoo.com - November 23 at 6:26 AM
|ETFs with exposure to MEI Pharma, Inc. : November 20, 2017|
finance.yahoo.com - November 21 at 5:43 AM
|MEI Pharma (MEIP) Presents At Stifel 2017 Healthcare Conference - Slideshow|
seekingalpha.com - November 17 at 3:58 PM
|Oppenheimer Holdings Brokers Increase Earnings Estimates for MEI Pharma, Inc. (MEIP)|
www.americanbankingnews.com - November 13 at 6:34 AM
|MEI Pharma, Inc. :MEIP-US: Earnings Analysis: Q1, 2018 By the Numbers : November 9, 2017|
finance.yahoo.com - November 12 at 6:20 AM
|ETFs with exposure to MEI Pharma, Inc. : November 10, 2017|
finance.yahoo.com - November 12 at 6:20 AM
|Galectin Therapeutics (GALT) in Focus: Stock Moves 6.5% Higher|
www.zacks.com - October 12 at 12:17 AM
|Insmed (INSM) & MEI Pharma (MEIP) Head-To-Head Contrast|
www.americanbankingnews.com - October 4 at 4:32 PM
|AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher|
www.zacks.com - October 3 at 10:16 AM
|MEI Pharma to Present at Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 20 at 6:16 AM
|Featured Company News - Teva Pharmaceuticals Presents Outcome Measure Results from Phase-III Clinical Trials for the Potential of Fremanezumab to Treat Migraine Patients|
finance.yahoo.com - September 13 at 6:29 AM
|MEI Pharma (MEIP) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow|
seekingalpha.com - September 12 at 1:07 AM
|Oppenheimer Holdings Equities Analysts Reduce Earnings Estimates for MEI Pharma, Inc. (MEIP)|
www.americanbankingnews.com - September 11 at 4:44 AM
MEI Pharma (NASDAQ:MEIP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MEI Pharma (NASDAQ:MEIP) Income Statement, Balance Sheet and Cash Flow Statement
MEI Pharma (NASDAQ MEIP) Stock Chart for Saturday, April, 21, 2018